Ethics in Pharmaceuticals

19 posts

Doctors & Pharma Industry – Part 2 of 2 – Asrar Qureshi’s Blog Post #1218

Asrar Qureshi’s Blog Post #1218 addresses the complex relationship between pharmaceutical companies and doctors, emphasizing the need for ethical conduct in Pakistan’s healthcare system. It outlines a Code of Conduct for both sectors, aiming to balance industry collaboration with patient welfare, maintaining professionalism while avoiding conflicts of interest.
Share
View Post
  • 5 min

Doctors & Pharma Industry – Part 1 of 2 – Asrar Qureshi’s Blog Post 1217

The blog post by Asrar Qureshi explores the complex relationship between pharmaceutical companies and doctors, emphasizing its dual nature of necessity and ethical risk. It advocates for transparency and independence in education, particularly in the context of Pakistan’s healthcare challenges. The post highlights both issues and contributions of this relationship in improving patient access to treatment.
Share
View Post
  • 5 min

Recent Drug Safety Alerts – Asrar Qureshi’s Blog Post #1125

Asrar Qureshi’s Blog Post 1125 discusses post-marketing surveillance and pharmacovigilance efforts in reporting adverse drug reactions. It highlights recent FDA warnings about cetirizine, scopolamine patches, and mRNA COVID-19 vaccines concerning severe side effects, urging that this information be treated as essential for discussions among healthcare professionals.
Share
View Post
  • 6 min

Colossal Wrongdoings by Big Pharma – Pfizer and COVID-19 Vaccine – Asrar Qureshi’s Blog Post #1095

Asrar Qureshi’s final blog post on Big Pharma critiques Pfizer’s handling during the COVID-19 pandemic, highlighting aggressive contract negotiations and lack of transparency. While Pfizer’s vaccine was pivotal globally, its commercial tactics raised ethical concerns and exposed power imbalances, prompting calls for reforms in pharmaceutical governance to prioritize public health over profits.
Share
View Post
  • 5 min

Colossal Wrongdoings by Big Pharma – Servier – Asrar Qureshi’s Blog Post #1094

Benfluorex, marketed as Mediator, was widely prescribed for diabetes and weight loss in France until its 2009 withdrawal due to severe health risks, causing 500-2,000 deaths. Dr. Irène Frachon’s investigation revealed systemic regulatory failures and corporate negligence. The scandal prompted significant reforms in France’s drug safety oversight to enhance transparency and accountability.
Share
View Post
  • 5 min

Colossal Wrongdoings by Big Pharma – Ranbaxy Scandal – Asrar Qureshi’s Blog Post #1093

The Ranbaxy scandal illustrates significant fraud within a major Indian pharmaceutical company that misled regulatory bodies and compromised drug safety. Whistleblower Dinesh Thakur’s revelations led to a $500 million settlement, exposing flaws in oversight and raising questions about generics. It’s a vital lesson on ethical standards and regulatory vigilance in the industry.
Share
View Post
  • 6 min

Colossal Wrongdoings by Big Pharma – Insulin Price Gouging – Asrar Qureshi’s Blog Post #1092

The blog post discusses the insulin price gouging crisis that began around 2000, with prices soaring due to manipulation by major manufacturers Eli Lilly, Novo Nordisk, and Sanofi. This crisis has significant implications for patients’ health and financial well-being, highlighting ethical issues in pharmaceutical capitalism and calling for urgent reform to ensure accessibility.
Share
View Post
  • 6 min

Colossal Wrongdoings by Big Pharma – Johnson & Johnson – Asrar Qureshi’s Blog Post #1091

Johnson & Johnson’s talcum powder scandal reveals a troubling history of alleged asbestos contamination and corporate negligence. Despite decades of evidence suggesting health risks, the company continued to market its products as safe. The backlash resulted in thousands of lawsuits, reputational damage, and a shift towards cornstarch alternatives as trust eroded.
Share
View Post
  • 5 min

Colossal Wrongdoings by Big Pharma – GSK – Asrar Qureshi’s Blog Post #1090

Asrar Qureshi’s blog post on Pharma Veterans highlights the systemic issues within the pharmaceutical industry, exemplified by GlaxoSmithKline’s $3 billion settlement for fraud and misconduct in 2012. The case underscores the need for stronger regulatory oversight, ethical practices, and whistleblower protection to prevent future harmful corporate behavior in healthcare.
Share
View Post
  • 5 min

Colossal Wrongdoings by Big Pharma – Vioxx – Asrar Qureshi’s Blog Post #1089

Asrar Qureshi’s blog post discusses the Vioxx scandal, highlighting Big Pharma’s greed and ethical failures. Vioxx, promoted as a painkiller, concealed severe cardiovascular risks, leading to thousands of health issues. Merck faced substantial lawsuits and settlements, yet corporate accountability remains questionable, emphasizing the need for stronger regulation and transparency in pharmaceuticals.
Share